摘要
目的探讨胰腺癌患者手术前后血清钙结合蛋白A9复合物(S100A9)、基质金属蛋白酶9(MMP-9)水平变化及其相关性。方法选取本院2016年5月至2018年2月60例行手术治疗的原发性胰腺癌患者作为胰腺癌组,另选取30例同期于本院进行健康体检者作为对照组,检测胰腺癌组患者手术前后以及对照组血清S100A9、MMP-9水平,分析两项指标的相关性,研究其与临床病理及预后的关系。结果血清S100A9、MMP-9含量:术前>术后7 d>术后1个月>对照组,差异均有统计学意义(P<0.05)。胰腺癌组患者术前、术后7 d、术后1个月血清S100A9水平与血清MMP-9含量呈现正相关(r=0.341、0.314、0.303,均P<0.05)。胰腺癌组患者术前肿瘤>4 cm、肿瘤分化程度低、临床分期Ⅲ期或Ⅳ期、淋巴结转移患者血清S100A9、MMP-9含量高于肿瘤≤4 cm、肿瘤分化程度高、临床分期Ⅰ期或Ⅱ期、未发生淋巴结转移者,差异均有统计学意义(P<0.05)。高S100A9表达患者2年生存率6.45%低于低S100A9表达患者的27.59%,中位生存时间14.7个月短于低S100A9表达患者的19.1个月,差异均有统计学意义(P<0.05)。高MMP-9表达患者2年生存率8.57%低于低MMP-9表达患者的28.00%,中位生存时间15.3个月短于低MMP-9表达患者的18.6个月,差异均有统计学意义(P<0.05)。结论胰腺癌患者术前血清S100A9、MMP-9高表达与临床病理相关,术后血清S100A9、MMP-9高表达患者预后差。
Objective To explore the changes and correlation of serum S100 calcium-binding protein A9(S100 A9)and matrix metalloproteinase-9(MMP-9)before and after surgery in patients with pancreatic cancer.Methods Sixty patients with primary pancreatic cancer undergoing surgery in the hospital were enrolled as the pancreatic cancer group from May 2016 to February 2018,while other 30 healthy controls during the same period were enrolled as the control group.The levels of serum S100 A9 and MMP-9 in two groups were detected.The correlation between the two indicators was analyzed.The relationship with clinicopathology and prognosis was studied.Results The levels of serum S100 A9 and MMP-9 in the pancreatic cancer group were higher than those in the control group before and after surgery(P<0.05).The levels of serum S100 A9 and MMP-9 at 7 d and 1 month after surgery were lower than those before surgery in the pancreatic cancer group(P<0.05).In pancreatic cancer group,level of serum S100 A9 was positively correlated with serum MMP-9 before surgery,at 7 d and 1 month after surgery(r=0.341,0.314,0.303,P<0.05).In the pancreatic cancer group,the levels of serum S100 A9 and MMP-9 in patients with tumors longer than 4 cm,low differentiation,clinical staging at stageⅢandⅣ,and lymph node metastasis were higher than those with tumors not longer than 4 cm,high differentiation,clinical staging at stageⅠandⅡ,and without metastasis(P<0.05).The 2-year survival rate in the 31 patients with high S100 A9 expression was lower than that with low S100 A9 expression[6.45%vs 27.59%(13/29)],and the median survival time was shorter than that with low S100 A9 expression(14.7 months vs 19.1 months)(P<0.05).The 2-year survival rate in patients with high MMP-9 expression was lower than that with low MMP-9 expression[8.57%28.00%],and the median survival time was shorter than that with low MMP-9 expression(15.3 months vs 18.6 months)(P<0.05).Conclusion The preoperative high expressions of serum S100 A9 and MMP-9 are related to clinicopathology in patients with pancreatic cancer.The prognosis is poor in patients with postoperative high expressions of serum S100 A9 and MMP-9.
作者
朱晓龙
张光亮
裴建灰
朱乐恒
ZHU Xiaolong;ZHANG Guangliang;PEI Jianhui;ZHU Leheng(Department of General Surgery,General Hospital of Pingmei Shenma Medical Group,Pingdingshan,Henan,China,467000)
出处
《分子诊断与治疗杂志》
2021年第11期1846-1849,共4页
Journal of Molecular Diagnostics and Therapy
基金
河南省科技计划项目(162102210416)。